Aptorum Stock Tumbles 39% Amid DiamiR Biosciences Merger
By ATTN Desk · Editorial oversight: Sean Han
Introduction
APTORUM GROUP LIMITED (Nasdaq: APM) is a biotechnology research company headquartered in London, England. As of August 22, 2025, its ordinary shares closed at USD 2.5798, reflecting a 39.30% decrease on the day, with trading volume of 3,973,409 shares. The company’s mission is to facilitate medical innovations that address unmet clinical needs and improve patient care.
Corporate Structure
Founded in 2010 by Mr. Ian Huen, Aptorum Group Limited employs between 11 and 50 staff across disciplines that include pharmaceutical development, diagnostics, and life-science research. The firm operates as a public company listed on the Nasdaq Capital Market and collaborates with academic institutions and third-party suppliers to advance its pipeline.
Biotechnology by Sangharsh Lohakare
Developments and News
In its Form 6-K filing dated July 22, 2025, Aptorum disclosed the execution of a merger agreement with DiamiR Biosciences Corp. The agreement, signed on July 14, 2025, includes:
- Domestication as a Delaware corporation
- A stock conversion ratio and ownership structure to reflect combined operations
- A licensing arrangement granting Aptorum Therapeutics rights to DiamiR’s intellectual property
On April 30, 2025, the company filed its annual Form 20-F, which outlines its global research activities and focus on therapeutic and diagnostic assets. An amended Schedule 13G/A, filed May 15, 2025, reported that L1 Capital Global Opportunities Master Fund, Ltd. indicated zero beneficial ownership of Class A ordinary shares.
Aptorum’s official website and corporate pipeline page detail its focus on early-stage diagnostics for neurodegenerative diseases, oncology, and other disorders, as well as therapeutic candidates aimed at improving surgical outcomes and clinical management.
Financial and Strategic Analysis
On August 22, 2025, Aptorum’s share price was USD 2.5798, down from a previous close of USD 4.25. According to Yahoo Finance data:
| Metric | Value |
|---|---|
| Market Capitalization | USD 30.36 million |
| Enterprise Value | USD 32.84 million |
| 52-Week Range | USD 0.46–7.49 |
| Trailing P/E Ratio | N/A |
| EPS (TTM) | –0.78 |
| Net Loss (TTM) | USD 4.27 million |
| Return on Assets (TTM) | –8.33% |
| Return on Equity (TTM) | –30.62% |
| Total Cash (MRQ) | USD 0.87 million |
| Total Debt/Equity (MRQ) | 28.49% |
| Levered Free Cash Flow (TTM) | –USD 1.96 million |
Aptorum’s strategic focus is on integrating DiamiR’s molecular diagnostics platform to develop minimally invasive tests for early detection of neurodegenerative and oncological conditions. The management services agreement and licensing arrangement aim to support research and development for a glioblastoma diagnostic test. These initiatives may contribute to the company’s goal of building an intellectual property-based portfolio, subject to regulatory approvals and successful clinical validation.
Market Position and Industry Context
Aptorum operates in the biotechnology sector, which is characterized by significant capital requirements and regulatory oversight by agencies such as the U.S. Food and Drug Administration. The firm’s focus on diagnostics for difficult-to-detect diseases positions it alongside companies developing liquid biopsies, imaging agents, and molecular assays. Ongoing challenges include securing additional capital, meeting clinical milestones, and managing operational integration post-merger.
TL;DR
On August 22, 2025, APM shares closed at USD 2.5798, reflecting a 39.30% decrease in trading volume near 4 million shares. The company filed a Form 6-K on July 22, 2025, detailing its merger agreement with DiamiR Biosciences Corp., which involves a new corporate structure in Delaware and expanded diagnostic capabilities. Key metrics indicate a market capitalization of USD 30.36 million and a trailing EPS of –0.78. The outcomes of regulatory processes and clinical developments related to DiamiR’s technology will impact Aptorum’s future direction.